OncologyTube Professional - Patients Click Here
Lymphoma-Myeloma-Conference
1,372 video views
Loading........
Description: Raje, Noopur MD of the Massachusetts General Hospital Cancer Center highlights that denosumab now gives clinicians more choices for treating multiple myeloma.
00:29
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center highlights that denosumab now gives clinicians more choices for treating multiple myeloma.
00:48
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center discusses the next steps for Denosumab at the Lymphoma-Myelom​a 2017 meeting in New York.
00:53
Raje, Noopur S., MD from Massachusetts General Hospital Cancer Center asks the question is it possible to switch from one bone targeting agent to another in multiple myeloma?
00:53
Raje, Noopur, MD of Massachusetts General Hospital Cancer Center discusses if it is possible to switch from one bone targeting agent to another in Multiple Myeloma?
02:21
Noopur Raje, MD of Massachusetts General Hospital Cancer Center outlines how the recently released economic analysis of Denosumab v. Zoledronic Acid found that Denosumab was overall more cost effective. Dr. Raje presented these findings at the 2017 Lymphoma-Myelom​a meeting in New York.
02:16
Noopur Raje, MD of Massachusetts General Hospital Cancer Center discusses her findings in which Denosumab is favored in newly diagnosed multiple myeloma patients from a recent economic analysis of Denosumab v Zoledronic Acid in Multiple Myeloma at the 2017 Lymphoma and Myeloma meeting in New York.

About Lymphoma-Myeloma-Conference


Links
Channel Url: